These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 22558487)

  • 1. Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.
    Vugmeyster Y; Xu X; Theil FP; Khawli LA; Leach MW
    World J Biol Chem; 2012 Apr; 3(4):73-92. PubMed ID: 22558487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonclinical Development of Biologics: Integrating Safety, Pharmacokinetics, and Pharmacodynamics to Create Smarter and More Flexible Nonclinical Safety Programs Optimizing Animal Use.
    Hey A; Baumann A; Kronenberg S; Blaich G; Mohl S; Fagg R; Ulrich P; Rattel B; Richter WF; Kiessling A; Weir L
    Int J Toxicol; 2021; 40(3):270-284. PubMed ID: 33631988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies.
    Kamath AV
    Drug Discov Today Technol; 2016; 21-22():75-83. PubMed ID: 27978991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs.
    Colbert A; Umble-Romero A; Prokop S; Chow VF; Wong T; DeSimone D; Zhou L; Pederson S
    MAbs; 2014; 6(5):1178-89. PubMed ID: 25517303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies.
    Lynch CM; Hart BW; Grewal IS
    MAbs; 2009; 1(1):2-11. PubMed ID: 20046568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are Biotransformation Studies of Therapeutic Proteins Needed? Scientific Considerations and Technical Challenges.
    Schadt S; Hauri S; Lopes F; Edelmann MR; Staack RF; Villaseñor R; Kettenberger H; Roth AB; Schuler F; Richter WF; Funk C
    Drug Metab Dispos; 2019 Dec; 47(12):1443-1456. PubMed ID: 31748266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and advances in the assessment of the disposition of antibody-drug conjugates.
    Kamath AV; Iyer S
    Biopharm Drug Dispos; 2016 Mar; 37(2):66-74. PubMed ID: 25904406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions.
    Vugmeyster Y; Harrold J; Xu X
    AAPS J; 2012 Dec; 14(4):714-27. PubMed ID: 22798020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies.
    Samineni D; Girish S; Li C
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1557-1569. PubMed ID: 27766899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.
    Brennan FR; Andrews L; Arulanandam AR; Blumel J; Fikes J; Grimaldi C; Lansita J; Loberg LI; MacLachlan T; Milton M; Parker S; Tibbitts J; Wolf J; Allamneni KP
    Regul Toxicol Pharmacol; 2018 Oct; 98():98-107. PubMed ID: 30026135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
    Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
    Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review.
    Loisios-Konstantinidis I; Paraiso RLM; Fotaki N; McAllister M; Cristofoletti R; Dressman J
    J Pharm Pharmacol; 2019 Apr; 71(4):699-723. PubMed ID: 30793317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonclinical safety testing of biopharmaceuticals--Addressing current challenges of these novel and emerging therapies.
    Brennan FR; Baumann A; Blaich G; de Haan L; Fagg R; Kiessling A; Kronenberg S; Locher M; Milton M; Tibbitts J; Ulrich P; Weir L
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):265-75. PubMed ID: 26219199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of pharmacokinetics as an interpretive and predictive tool in chemical toxicology testing and risk assessment: a position paper on the appropriate use of pharmacokinetics in chemical toxicology.
    Frantz SW; Beatty PW; English JC; Hundley SG; Wilson AG
    Regul Toxicol Pharmacol; 1994 Jun; 19(3):317-37. PubMed ID: 8090955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonclinical development of biopharmaceuticals.
    Baumann A
    Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generating Robust and Informative Nonclinical
    Bulitta JB; Hope WW; Eakin AE; Guina T; Tam VH; Louie A; Drusano GL; Hoover JL
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions.
    Tang Y; Cao Y
    Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33800976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development.
    Lee JW; Kelley M; King LE; Yang J; Salimi-Moosavi H; Tang MT; Lu JF; Kamerud J; Ahene A; Myler H; Rogers C
    AAPS J; 2011 Mar; 13(1):99-110. PubMed ID: 21240643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
    Liu L
    J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.